Form 8-K - Current report:
SEC Accession No. 0001193125-24-244185
Filing Date
2024-10-25
Accepted
2024-10-25 16:45:57
Documents
11
Period of Report
2024-10-23
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 3.02: Unregistered Sales of Equity Securities
Item 5.03: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d847969d8k.htm 8-K 33893
2 EX-1.1 d847969dex11.htm EX-1.1 230882
3 EX-3.1 d847969dex31.htm EX-3.1 289221
4 EX-4.1 d847969dex41.htm EX-4.1 110820
5 EX-10.1 d847969dex101.htm EX-10.1 271594
6 EX-10.2 d847969dex102.htm EX-10.2 92874
7 EX-10.3 d847969dex103.htm EX-10.3 116065
8 EX-10.4 d847969dex104.htm EX-10.4 51053
9 EX-10.5 d847969dex105.htm EX-10.5 18982
10 EX-99.1 d847969dex991.htm EX-99.1 9138
11 GRAPHIC g847969g1023202248508.jpg GRAPHIC 6320
  Complete submission text file 0001193125-24-244185.txt   1234763
Mailing Address 333 SOUTH GRAND AVENUE, 28TH FLOOR LOS ANGELES CA 90071
Business Address 333 SOUTH GRAND AVENUE, 28TH FLOOR LOS ANGELES CA 90071 213-830-6300
Oaktree Acquisition Corp. III Life Sciences (Filer) CIK: 0002029769 (see all company filings)

EIN.: 000000000 | State of Incorp.: E9 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-42383 | Film No.: 241397574
SIC: 6770 Blank Checks
(CF Office: 05 Real Estate & Construction)